Deakin University
Browse

File(s) not publicly available

Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

Version 2 2024-06-13, 14:35
Version 1 2021-09-20, 08:11
journal contribution
posted on 2024-06-13, 14:35 authored by DJ McGrail, PG Pilié, NU Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, AB Heimberger, NT Ueno, R Ferrarotto, JT Chang, SY Lin
Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.

History

Journal

Annals of Oncology

Volume

32

Pagination

1194-1197

Location

England

ISSN

0923-7534

eISSN

1569-8041

Language

en

Publication classification

C4 Letter or note

Issue

9

Publisher

Elsevier BV